Form 4: Jennifer Doudna Receives JNJ Deferred Share Units

Sentiment:

Statement of Changes in Beneficial Ownership


Director Jennifer A. Doudna acquired 975 deferred share units as part of the Johnson & Johnson director compensation plan.

Summary

  • Director Jennifer A. Doudna was granted 975 deferred share units (DSUs) on April 23, 2026.
  • These units are part of the Issuer's Amended and Restated Deferred Fee Plan for Directors.
  • The DSUs will be settled in cash upon the termination of Doudna's directorship.
  • Following this transaction, Doudna holds a total of 10,899.1714 deferred share units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.

Positives

  • Alignment of director interests with long-term company performance through equity-linked compensation.

Negatives

  • None identified.

Risks

  • Value of deferred share units is subject to the future market performance of Johnson & Johnson common stock.

Future Outlook

The deferred share units will be settled in cash upon the termination of the reporting person's directorship, with the value tied to the fair market value of common stock at that time.

Industry Context

StockSavvy.ai notes that this is a routine disclosure of director compensation, common among large-cap pharmaceutical companies to ensure board members maintain a financial stake in the company's long-term success.

Comparison to Industry Standards

  • The use of deferred share units for director compensation is a standard corporate governance practice among S&P 500 companies.
  • The structure aligns with compensation models used by peers such as Pfizer and Merck.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Director CompensationGrant of deferred share units under the Amended and Restated Deferred Fee Plan for Directors.2026-04-23Standard compensation practice; no material impact on governance.

Stakeholder Impact

  • Minimal impact on shareholders as this is a standard component of director compensation.

Next Steps

  • Settlement of deferred share units upon the future termination of the director's service.

Key Dates

DateDescription
2025-12-04Date of Power of Attorney execution.
2026-04-23Date of the deferred share unit grant transaction.
2026-04-27Date of filing.

Keywords

Johnson & Johnson, JNJ, Director Compensation, Deferred Share Units, Insider Transaction, Jennifer Doudna

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.